A detailed history of Price T Rowe Associates Inc transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 17,396 shares of OVID stock, worth $17,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,396
Previous 17,396 -0.0%
Holding current value
$17,917
Previous $14,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.72 - $4.04 $8,554 - $12,705
3,145 Added 22.07%
17,396 $54,000
Q4 2023

Feb 14, 2024

BUY
$2.98 - $3.78 $2,494 - $3,163
837 Added 6.24%
14,251 $46,000
Q3 2023

Nov 14, 2023

BUY
$3.23 - $3.97 $4,202 - $5,164
1,301 Added 10.74%
13,414 $52,000
Q2 2023

Aug 14, 2023

SELL
$2.53 - $3.89 $38,929 - $59,855
-15,387 Reduced 55.95%
12,113 $40,000
Q3 2022

Nov 14, 2022

SELL
$1.84 - $2.26 $6,684 - $8,210
-3,633 Reduced 11.67%
27,500 $51,000
Q2 2022

Aug 15, 2022

SELL
$1.69 - $3.31 $11,539 - $22,600
-6,828 Reduced 17.99%
31,133 $67,000
Q2 2021

Aug 16, 2021

BUY
$3.3 - $4.49 $4,002 - $5,446
1,213 Added 3.3%
37,961 $148,000
Q1 2021

May 17, 2021

BUY
$2.42 - $4.47 $88,930 - $164,263
36,748 New
36,748 $148,000

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $72.5M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.